Form 4: Roivant Sciences Officer's RSU Tax Settlement

Roivant Sciences' President & Immunovant CEO, Eric Venker, reported a net settlement of 7,051 common shares for tax withholding related to RSU vesting.

Summary

• Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., reported a transaction on November 20, 2025.
• The transaction involved the disposition of 7,051 common shares through a 'net settlement' to satisfy tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• The shares were valued at $20.27 per share for the purpose of this tax settlement.
• Following this transaction, Eric Venker beneficially owns 1,497,908 common shares directly.
• The filing indicates that this transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (RSU tax withholding). It does not indicate any material positive or negative operational or financial developments for the company, thus maintaining a neutral sentiment.

Positives

• The underlying vesting of Restricted Stock Units (RSUs) indicates continued executive compensation and retention of a key officer.
• Eric Venker retains a substantial beneficial ownership of 1,497,908 common shares after the transaction.

Negatives

• The disposition of 7,051 common shares, even for tax purposes, reduces the direct beneficial ownership of the reporting person.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The filing was signed by Jo Chen, as Attorney-in-Fact for Eric Venker.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation. The net settlement of Restricted Stock Units (RSUs) for tax withholding is a common and expected event for executives in publicly traded companies, reflecting the standard practice of equity-based compensation.

Comparison to Industry Standards

• The practice of net settlement for RSU tax withholding is a standard industry practice for executive compensation across various sectors, including biotechnology and pharmaceuticals, where equity awards are a significant component of remuneration.
• This transaction aligns with typical compensation structures seen in comparable companies within the life sciences industry, where executives receive RSUs that vest over time, leading to such tax-related dispositions upon vesting.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation and does not reflect a change in company fundamentals or strategic direction.
• Employees: No direct impact mentioned, but it reflects standard executive compensation practices.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary transaction where an executive's vested Restricted Stock Units (RSUs) were net-settled to cover tax withholding obligations. Such transactions are common for executive compensation and do not typically reflect a discretionary investment decision or provide new insights into the company's operational or financial performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Roivant Sciences, ROIV, Eric Venker, Form 4, RSU, stock transaction, insider trading, beneficial ownership, tax withholding, executive compensation